Table 1.
Clinical Characteristics of Participants
| PMD | NPMD | P value* | |
|---|---|---|---|
| Number | 56 | 52 | |
| Age, years | .42 | ||
| Mean (SD) | 71.7 (7.7) | 70.2 (6.7) | |
| Median (IQR) | 70.0 (65.8–77.0) | 69.0 (65.0–75.3) | |
| Female | 35 | 32 | .76 |
| (62.5%) | (65.4%) | ||
| HAM-D before ECT | .001 | ||
| Mean (SD) | 30.5 (8.3) | 24.6 (5.2) | |
| Median (IQR) | 31.1 (24.2–37.6) | 24.8 (20.6–27.7) | |
| HAM-D after ECT | .38 | ||
| Mean (SD) | 5.1 (6.5) | 6.1 (7.3) | |
| Median (IQR) | 3.0 (1.0–7.9) | 4.0 (0.8–9.0) | |
| %change of HAM-D scores | .17 | ||
| Mean (SD) | 82.4 (22.8) | 74.3 (31.7) | |
| Median (IQR) | 89.3 (75.4–97.5) | 82.7 (67.1–96.8) | |
| Response rate | 51/55 | 42/52 | .10 |
| (92.8%) | (80.8%) | ||
| Remission rate | 41/56 | 37/52 | .81 |
| (73.2%) | (71.2%) | ||
| Number of ECT session | .10 | ||
| Mean (SD) | 12.2 (4.5) | 11.2 (5.0) | |
| Median (IQR) | 12.0 (9.0–14.3) | 10.5 (8.8–13.0) | |
| Electrode placement | .93 | ||
| RUL | 31 (55.4%) | 30 (57.7%) | |
| BT | 15 (26.8%) | 12 (23.1%) | |
| RUL to BT | 10 (17.9%) | 10 (19.2%) | |
| Medications | |||
| Antidepressants | 30 (53.6%) | 33 (63.5%) | .30 |
| Antipsychotics | 22 (39.3%) | 20 (38.5%) | .93 |
| Lithium | 1 (1.8%) | 3 (5.8%) | .30 |
| Benzodiazepine | 10 (17.9%) | 10 (19.2%) | 1.0 |
Abbreviations: BT, bitemporal; HAM-D, Hamilton Depression Rating Scale; IQR, interquartile range; NPMD, nonpsychotic major depression; PMD, psychotic major depression; RUL, right unilateral.
*Differences in participants’ characteristics between groups were examined using independent t test (HAM-D before ECT) or Mann-Whitney U test (age, HAM-D after ECT, %change of HAM-D scores, Number of ECT sessions) for continuous variables, and χ 2 analysis (Response rate, Remission rate, Antidepressants, Antipsychotics) or Fisher exact test (Electrode placement, Lithium) for categorical variables. Each test was selected in accordance with the distribution of each variable.